Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Therapy Type (Drug Therapy (Gemcitabine Combination Therapy,5-fluorouracil Combination Therapy, Capecitabine Combination Therapy and Gemcitabine Alone) Radiation Therapy (Brachytherapy and External Beam Radiation Therapy (EBRT), and Surgery), By Disease Indication (Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer and Distal Extrahepatic Bile Duct Cancer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region Forecast 2020-2031

Bile duct cancer treatment market size was valued at US$ 3.9 billion in 2024 and is expected to reach US$ 6.9 billion by 2031, growing at a significant CAGR of 8.5% from 2025-2031. Bile duct cancer, also known as cholangiocarcinoma, refers to a type of cancer that originates in the bile ducts, which are the tubes that carry bile from the liver to the small intestine. Bile duct cancer can occur in different parts of the bile duct system, including the intrahepatic bile ducts (inside the liver), the perihilar bile ducts (where the ducts exit the liver), and the distal bile ducts (closer to the small intestine). Treatment for bile duct cancer is determined based on the stage of the cancer, its location, the patient's overall health, and other individual factors.

The increasing incidence of bile duct cancer (cholangiocarcinoma) and the growing awareness of this disease are pivotal drivers propelling the growth of the market. As per the American Cancer Society, every year in the United States, around 8,000 people are diagnosed with Bile duct cancer. As the prevalence of cholangiocarcinoma rises, there is a heightened demand for effective treatment options to address this challenging condition. Simultaneously, greater awareness among healthcare providers, patients, and the general population has led to earlier detection and diagnosis, enabling timely intervention. This increased recognition of cholangiocarcinoma's significance has spurred research efforts and the development of innovative treatment modalities, including targeted therapies, surgical advancements, and personalized medicine approaches.

Moreover, advancements in medical science play a pivotal role in driving the revenues of the cholangiocarcinoma treatment market. As our understanding of the molecular and genetic intricacies of cholangiocarcinoma deepens, novel avenues for targeted therapies and personalized treatment strategies emerge. These advancements enable healthcare professionals to develop more precise and effective interventions tailored to the specific characteristics of each patient's tumor. However, the complexity, heterogeneity, and limited understanding of the disease's underlying mechanisms can pose challenges in developing effective treatment options.

Meanwhile, recent advancements in immunotherapy, particularly immune checkpoint inhibitors, hold promise for revolutionizing cancer treatment outcomes and expanding the market. Furthermore, key market players are developing innovative solutions to treat cholangiocarcinoma. For example, in September 2022, Taiho Oncology, Inc. announced the U.S. Food and Drug Administration (FDA) approval of LYTGOBI tablets for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA).

Key Developments

• In September 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
• In April 2020, Incyte announced the approval of the Pemigatinib for treatment of certain adults with previously treated unresectable cholangiocarcinoma.